The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects
Study Identifier
P15-349
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Study Details
Medical Condition
Study Drug
N/A
Phase
N/A
Sex
Female & Male
Age
18 - 75 Years
Protocol Summary
This study seeks to assess the durability of response and persistence of resistance to ombitasvir/ paritaprevir/ritonavir in Japanese participants who enrolled in a Phase 2 or 3 clinical study with these agents for the treatment of chronic hepatitis C.
Study Locations
Location
Status
Location
Nagoya City University Hospital /ID# 157439
Nagoya, Aichi-ken, Japan, 467-8602
Status
Not applicable
Location
Matsuyama Red Cross Hospital /ID# 152125
Matsuyama, Ehime, Japan, 790-8524
Status
Not applicable
Location
National Hospital Organization Kyushu Medical Center /ID# 161759
Fukuoka, Fukuoka, Japan, 810-8563
Status
Not applicable
Location
Fukuoka University Hospital /ID# 155965
Fukuoka, Fukuoka, Japan, 814-0180
Status
Not applicable
Location
Kurume University Hospital /ID# 152123
Kurume-shi, Fukuoka, Japan, 830-0011
Status
Not applicable
Location
Ogaki Municipal Hospital /ID# 158105
Ogaki-shi, Gifu, Japan, 503-8502
Status
Not applicable
Showing {first} - {last} of {total} Results